Business Model and Financing
NK Bioscience needs seed investment to continue prosecuting the patent, hire staI and conduct the necessary experimental work. We need to establish our own facilities. To date, we have been using shared facilities at the Life Sciences Innovation Hub at the University of Calgary campus. In 2025, over about seven months, we have created the cell lines and need financial support to extend those studies in the following ways:
Extend studies to other tumor cell lines and demonstrate lack of activity against normal cells
Conduct studies against tumor organoids
(3-dimensional tumors) in vitro and implanted tumors in mice
Characterize the engineered NK-cells fully
Continue to pursue patent protection
We expect to complete studies in six to nine months, and following that, we will be raising a Series A investment to conduct preclinical and Phase 1/2A clinical trials. Our strategy is to seek marketing partnerships or acquisitions following success in Phase 1/2A trials.
Competitive Advantage
EIorts to get around immunosuppression by the creation of CAR-NK therapies, by inhibitors of IDO, an enzyme that creates kynurenine, one of the factors which inactivates NK-cells, and by attempts to create eIective inhibitors of TGF B, a cytokine that also inactivates immune response, or by creating “stimulated” NK-cells, have all met with very limited success alone, or in combination with other therapies. Especially with aggressive tumors, these eIorts cannot recharge the tumor-killing activity of NK-cells. Tumors have several methods of suppressing the immune system, so any single approach is not likely to meet with success.
Our advantage is that NK Bio-engineered NK-cells are impervious to the immunosuppressive ability of solid tumors to inactivate them. They continue to kill tumor cells under conditions that completely inhibit normal NK-cells